Prevagen has not been shown to improve memory in healthy adults based on the available scientific evidence. Despite heavy television advertising claiming the supplement is “clinically shown” to help with mild memory problems associated with aging, the research behind those claims is thin, and federal regulators have successfully challenged them in court. Here’s what the science actually says.
What Prevagen Contains
Prevagen’s active ingredient is apoaequorin, a protein originally found in a species of jellyfish. The regular strength version contains 10 mg of apoaequorin per capsule, while the extra strength version contains 20 mg along with 50 mcg of vitamin D3. A 30-day supply of the regular strength costs roughly $48 at retail without insurance, making it one of the pricier supplements on the market.
The manufacturer, Quincy Bioscience, claims apoaequorin binds calcium inside brain cells in a way that supports cognitive function. That’s the theory. In practice, the protein faces a fundamental biological problem before it can do anything in the brain.
The Blood-Brain Barrier Problem
Apoaequorin is a protein, and proteins taken by mouth are broken down during digestion, just like the proteins in a chicken breast or an egg. The Alzheimer’s Drug Discovery Foundation reviewed the evidence and concluded there is strong reason to believe apoaequorin does not survive digestion in the gut. Even if fragments did survive, there is no evidence the protein crosses the blood-brain barrier, the tightly controlled gateway that determines what reaches brain tissue from the bloodstream.
This is a significant issue. If the active ingredient never reaches the brain intact, the proposed mechanism for how Prevagen works falls apart entirely. The Alzheimer’s Drug Discovery Foundation stated plainly that apoaequorin “is unlikely to have any effect on the brain.”
What the Manufacturer’s Own Study Found
Prevagen’s marketing relies heavily on a single clinical trial called the Madison Memory Study, published in the journal Advances in Mind-Body Medicine. The study enrolled 218 adults aged 40 to 91 who reported their own memory concerns. Participants took either apoaequorin or a placebo daily for 90 days.
The overall results showed no significant difference between the supplement group and the placebo group on the study’s primary measures. That’s the headline finding, and it matters more than anything else about this trial.
However, when the researchers went back and sliced the data into smaller subgroups, they found that participants who scored in a specific range on a cognitive screening tool showed improvement on a word-recall test: about 10.9% more items recalled correctly, and a 15.8% improvement on delayed recall. These subgroup numbers are what Prevagen’s advertising highlights.
Subgroup analysis like this is a well-known statistical pitfall. When you divide a study population into enough smaller groups and test each one separately, you increase the odds of finding a positive result by chance alone. Researchers generally treat subgroup findings as preliminary signals that need confirmation in a dedicated follow-up trial. No such confirmatory trial has been published. No independent research group, one without financial ties to Quincy Bioscience, has replicated these results.
What Regulators and Experts Have Said
In 2017, the Federal Trade Commission and the New York State Attorney General sued Quincy Bioscience, charging that the company made false and unsubstantiated claims that Prevagen improves memory, provides cognitive benefits, and is “clinically shown” to work. The case moved through the courts for years. In late 2024, the FTC announced a win in the lawsuit, with a memorandum, judgment, and order issued in November and December of that year.
The Global Council on Brain Health, an independent panel of scientists, doctors, and policy experts convened by AARP, conducted a broad evidence review of supplements marketed for brain health. Their conclusion was unambiguous: the council does not recommend any dietary supplement for brain health. They stated that scientific evidence does not support the use of any supplement to prevent, slow, reverse, or stop cognitive decline. They did not single out Prevagen specifically, but the product falls squarely under that umbrella. AARP estimated that roughly 983,000 Americans over age 50 were taking Prevagen despite the council’s conclusion that it lacks sufficient evidence of effectiveness.
Reported Side Effects
Because apoaequorin is likely broken down during digestion like any other dietary protein, the risk of serious side effects is low. That said, a review of 2,281 adverse events reported by consumers and compiled in a safety notification (which was later withdrawn) found that the most common complaints were headache (18.8% of reports), dizziness (7.5%), nausea (6.8%), and elevated blood pressure (3.7%). These are self-reported numbers, not rates from a controlled study, so they don’t prove the supplement caused those symptoms. But they are worth knowing about, particularly the headache reports.
What Actually Helps With Age-Related Memory
The interventions with the strongest evidence for preserving cognitive function as you age are not supplements. Regular aerobic exercise, even brisk walking for 150 minutes per week, consistently shows measurable benefits for memory and processing speed in older adults. Quality sleep, social engagement, and managing cardiovascular risk factors like high blood pressure and high blood sugar all have more scientific support than any pill marketed for brain health.
Cognitive stimulation, learning new skills, reading, or engaging in challenging mental activities, also has a solid evidence base. These activities don’t cost $48 a month, and the evidence behind them doesn’t depend on a single manufacturer-funded trial with questionable subgroup analysis.
If you’re spending money on Prevagen hoping it will sharpen your memory, the honest summary of the science is this: the protein it contains almost certainly doesn’t reach your brain, the one clinical trial behind it failed on its primary outcome measures, no independent researchers have confirmed any benefit, and federal regulators have successfully challenged the company’s marketing claims in court.